GPX4 and renal cell carcinoma: Although mGPX4‐specific inhibitors remain elusive, pan‐GPX4 inhibitors demonstrate significant efficacy in solid tumor models such as melanoma [657] and RCC [658], suggesting broad applicability of this pathway.